Important notice: Alluvi has never operated any social media accounts. Any profile using the Alluvi name is a scam. Alluviretatrutide.uk is the only official Alluvi website.Important notice: Alluvi has never operated any social media accounts. Any profile using the Alluvi name is a scam. Alluviretatrutide.uk is the only official Alluvi website.Important notice: Alluvi has never operated any social media accounts. Any profile using the Alluvi name is a scam. Alluviretatrutide.uk is the only official Alluvi website.
ALLUVI
Retatrutide 20mg (R&D Only)
← Back to Shop

Retatrutide 20mg

R&D Only

£99.99

8 weeks supply
Each Retatrutide 20mg Research kit includes pre-filled pens for controlled evaluation.

Delivery: Dispatched with a cold pack.
  • Pre-filled pen for consistent dosing
  • 8-week research supply
  • Cold pack delivery for stability
  • Batch-level purity documentation
  • Research & Development purposes only

Research & Development purposes only. Not for human or veterinary consumption.

Certificate of Analysis

Batch-tested quality assurance for research-grade material

Certificate of Analysis - Retatrutide 20mg

Quality Assurance Report

ProductRetatrutide 20mg (R&D Only)
Batch NumberRT-2401-B
Certificate IDRT-2401-C4827
Test DateJune 2026
Purity (HPLC)PASS
Identity (ESI-MS)PASS
EndotoxinPASS
StatusAPPROVED FOR RESEARCH USE
Verification: This certificate applies to batch RT-2401-B only. Each batch is independently tested using HPLC, ESI-MS, and USP methods.
Storage: -20°C. For research and development purposes only. Not for human or veterinary use.
Download Full Report (PDF)

Scientific References

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." N Engl J Med. 2023;389:514–526. PubMed
  2. Rosenstock J, Frias J, Jastreboff AM, et al. "Retatrutide, a GIP/GLP-1/Glucagon Receptor Agonist, for Type 2 Diabetes — A Phase 2 Study." N Engl J Med. 2023;389:1191–1203. PubMed
  3. Retatrutide — Wikipedia. Encyclopedia entry covering pharmacology, clinical trial data, and mechanism of action for this GIP/GLP-1/glucagon triple receptor agonist.

These references are provided for informational and research reference purposes. Alluvi does not claim that its products reproduce the results of cited studies. Products are supplied exclusively for controlled research and development purposes.